270 related articles for article (PubMed ID: 31182717)
1. SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers.
Jones GG; Del Río IB; Sari S; Sekerim A; Young LC; Hartig N; Areso Zubiaur I; El-Bahrawy MA; Hynds RE; Lei W; Molina-Arcas M; Downward J; Rodriguez-Viciana P
Nat Commun; 2019 Jun; 10(1):2532. PubMed ID: 31182717
[TBL] [Abstract][Full Text] [Related]
2. SHOC2 complex-driven RAF dimerization selectively contributes to ERK pathway dynamics.
Boned Del Río I; Young LC; Sari S; Jones GG; Ringham-Terry B; Hartig N; Rejnowicz E; Lei W; Bhamra A; Surinova S; Rodriguez-Viciana P
Proc Natl Acad Sci U S A; 2019 Jul; 116(27):13330-13339. PubMed ID: 31213532
[TBL] [Abstract][Full Text] [Related]
3. SHOC2-MRAS-PP1 complex positively regulates RAF activity and contributes to Noonan syndrome pathogenesis.
Young LC; Hartig N; Boned Del Río I; Sari S; Ringham-Terry B; Wainwright JR; Jones GG; McCormick F; Rodriguez-Viciana P
Proc Natl Acad Sci U S A; 2018 Nov; 115(45):E10576-E10585. PubMed ID: 30348783
[TBL] [Abstract][Full Text] [Related]
4. An MRAS, SHOC2, and SCRIB complex coordinates ERK pathway activation with polarity and tumorigenic growth.
Young LC; Hartig N; Muñoz-Alegre M; Oses-Prieto JA; Durdu S; Bender S; Vijayakumar V; Vietri Rudan M; Gewinner C; Henderson S; Jathoul AP; Ghatrora R; Lythgoe MF; Burlingame AL; Rodriguez-Viciana P
Mol Cell; 2013 Dec; 52(5):679-92. PubMed ID: 24211266
[TBL] [Abstract][Full Text] [Related]
5. Structure of the SHOC2-MRAS-PP1C complex provides insights into RAF activation and Noonan syndrome.
Bonsor DA; Alexander P; Snead K; Hartig N; Drew M; Messing S; Finci LI; Nissley DV; McCormick F; Esposito D; Rodriguez-Viciana P; Stephen AG; Simanshu DK
Nat Struct Mol Biol; 2022 Oct; 29(10):966-977. PubMed ID: 36175670
[TBL] [Abstract][Full Text] [Related]
6. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.
Lamba S; Russo M; Sun C; Lazzari L; Cancelliere C; Grernrum W; Lieftink C; Bernards R; Di Nicolantonio F; Bardelli A
Cell Rep; 2014 Sep; 8(5):1475-83. PubMed ID: 25199829
[TBL] [Abstract][Full Text] [Related]
7. KRAS
Zhou ZW; Ambrogio C; Bera AK; Li Q; Li XX; Li L; Son J; Gondi S; Li J; Campbell E; Jin H; Okoro JJ; Xu CX; Janne PA; Westover KD
Cancer Res; 2020 Sep; 80(17):3719-3731. PubMed ID: 32605999
[TBL] [Abstract][Full Text] [Related]
8. Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers.
Sulahian R; Kwon JJ; Walsh KH; Pailler E; Bosse TL; Thaker M; Almanza D; Dempster JM; Pan J; Piccioni F; Dumont N; Gonzalez A; Rennhack J; Nabet B; Bachman JA; Goodale A; Lee Y; Bagul M; Liao R; Navarro A; Yuan TL; Ng RWS; Raghavan S; Gray NS; Tsherniak A; Vazquez F; Root DE; Firestone AJ; Settleman J; Hahn WC; Aguirre AJ
Cell Rep; 2019 Oct; 29(1):118-134.e8. PubMed ID: 31577942
[TBL] [Abstract][Full Text] [Related]
9. Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer.
Kitai H; Ebi H; Tomida S; Floros KV; Kotani H; Adachi Y; Oizumi S; Nishimura M; Faber AC; Yano S
Cancer Discov; 2016 Jul; 6(7):754-69. PubMed ID: 27154822
[TBL] [Abstract][Full Text] [Related]
10. The scaffold protein Shoc2/SUR-8 accelerates the interaction of Ras and Raf.
Matsunaga-Udagawa R; Fujita Y; Yoshiki S; Terai K; Kamioka Y; Kiyokawa E; Yugi K; Aoki K; Matsuda M
J Biol Chem; 2010 Mar; 285(10):7818-26. PubMed ID: 20051520
[TBL] [Abstract][Full Text] [Related]
11. Classical RAS proteins are not essential for paradoxical ERK activation induced by RAF inhibitors.
Lai LP; Fer N; Burgan W; Wall VE; Xu B; Soppet D; Esposito D; Nissley DV; McCormick F
Proc Natl Acad Sci U S A; 2022 Feb; 119(5):. PubMed ID: 35091470
[TBL] [Abstract][Full Text] [Related]
12. Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers.
Hata AN; Yeo A; Faber AC; Lifshits E; Chen Z; Cheng KA; Walton Z; Sarosiek KA; Letai A; Heist RS; Mino-Kenudson M; Wong KK; Engelman JA
Cancer Res; 2014 Jun; 74(11):3146-56. PubMed ID: 24675361
[TBL] [Abstract][Full Text] [Related]
13. Structure of the MRAS-SHOC2-PP1C phosphatase complex.
Hauseman ZJ; Fodor M; Dhembi A; Viscomi J; Egli D; Bleu M; Katz S; Park E; Jang DM; Porter KA; Meili F; Guo H; Kerr G; Mollé S; Velez-Vega C; Beyer KS; Galli GG; Maira SM; Stams T; Clark K; Eck MJ; Tordella L; Thoma CR; King DA
Nature; 2022 Sep; 609(7926):416-423. PubMed ID: 35830882
[TBL] [Abstract][Full Text] [Related]
14. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
[TBL] [Abstract][Full Text] [Related]
15. Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling.
Rukhlenko OS; Khorsand F; Krstic A; Rozanc J; Alexopoulos LG; Rauch N; Erickson KE; Hlavacek WS; Posner RG; Gómez-Coca S; Rosta E; Fitzgibbon C; Matallanas D; Rauch J; Kolch W; Kholodenko BN
Cell Syst; 2018 Aug; 7(2):161-179.e14. PubMed ID: 30007540
[TBL] [Abstract][Full Text] [Related]
16. Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK.
Martinelli E; Morgillo F; Troiani T; Ciardiello F
Cancer Treat Rev; 2017 Feb; 53():61-69. PubMed ID: 28073102
[TBL] [Abstract][Full Text] [Related]
17. Structural basis for SHOC2 modulation of RAS signalling.
Liau NPD; Johnson MC; Izadi S; Gerosa L; Hammel M; Bruning JM; Wendorff TJ; Phung W; Hymowitz SG; Sudhamsu J
Nature; 2022 Sep; 609(7926):400-407. PubMed ID: 35768504
[TBL] [Abstract][Full Text] [Related]
18. mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells.
Komatsu N; Fujita Y; Matsuda M; Aoki K
Oncogene; 2015 Nov; 34(45):5607-16. PubMed ID: 25703330
[TBL] [Abstract][Full Text] [Related]
19. EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E-Mutant NSCLC Cell Lines.
Kim SM; Kim H; Jang KW; Kim MH; Sohn J; Yun MR; Kang HN; Kang CW; Kim HR; Lim SM; Moon YW; Kim JH; Paik S; Cho BC
Mol Cancer Ther; 2016 Jul; 15(7):1627-36. PubMed ID: 27196768
[TBL] [Abstract][Full Text] [Related]
20. RAF and MEK Inhibitors in Non-Small Cell Lung Cancer.
Adamopoulos C; Papavassiliou KA; Poulikakos PI; Papavassiliou AG
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
